Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Laurus Labs Limited
LAURUSLABSLaurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India. Address: Serene Chambers, Hyderabad, India, 500034
Analytics
Zielpreis von Wall Street
47 253.13 INRKGV
203.8163Dividendenrendite
0.17 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen LAURUSLABS
Dividenden-Analyse LAURUSLABS
Dividendenwachstum über 5 Jahre
433 %Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
37 %Verlauf der Dividende LAURUSLABS
Bewertung der Aktie LAURUSLABS
Finanzen LAURUSLABS
Ergebnisse | 2019 | Dynamik |